Solid Biosciences Announces FDA Removes Clinical Hold on SGT-001
June 18, 2018 07:00 ET
|
Solid Biosciences Inc.
- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway - Conference Call Scheduled for Today at 8:30 A.M. ET CAMBRIDGE, Mass., June 18, 2018 (GLOBE NEWSWIRE) --...
Solid Biosciences Announces New Preclinical Data at the American Society of Gene and Cell Therapy Annual Meeting
May 18, 2018 18:45 ET
|
Solid Biosciences Inc.
- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD - - Company Continues to Advance Gene Therapy Portfolio - CAMBRIDGE, Mass., May 18, 2018 (GLOBE NEWSWIRE)...
Solid Biosciences Announces Upcoming Preclinical Data Presentations
May 15, 2018 16:34 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its...
Solid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
May 10, 2018 07:30 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the first quarter ended March 31, 2018 and provided a business update. ...
Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy
April 18, 2018 07:30 ET
|
Solid Biosciences Inc.
- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks - - Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved - CAMBRIDGE, Mass.,...
Solid Biosciences Reports Full Year 2017 Financial Results and Provides Corporate Update
March 29, 2018 08:55 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., March 29, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update. ...
Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy
March 14, 2018 16:46 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration (FDA) that IGNITE...
Solid Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option
January 30, 2018 16:05 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the “Company” or “SLDB”), announced today the closing of its initial public offering of 8,984,375 shares of...
Solid Biosciences Announces Pricing of Initial Public Offering
January 25, 2018 18:56 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a price...